Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): Biodistribution and toxicity in a mouse model

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Sivak, Olena ^a   Gershkovich, Pavel ^a   Lin, Molly ^a   Wasan, Ellen K ^a,b   Zhao, Jinying ^a   Owen, David ^a   Clement, John G ^c   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

^c ICo Therapeutics Inc   (Canada)

Author keywords

Amphotericin B; Intestinal absorption; Lipid based formulation; Nephrotoxicity; Tissue distribution

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CREATININE; ICO 010; LIPID; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT;

ACUTE TOXICITY; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG FORMULATION; DRUG STABILITY; DRUG TISSUE LEVEL; FEMALE; HISTOPATHOLOGY; KIDNEY PARENCHYMA; LIVER; LIVER TOXICITY; LUNG PARENCHYMA; MOUSE; MUSCLE TISSUE; NEPHROTOXICITY; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; SKIN; SPLEEN; TISSUE DISTRIBUTION; TROPIC CLIMATE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DRUG SCREENING; KIDNEY; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ANIMALIA; MUS;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CREATININE; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FEMALE; KIDNEY; MICE; MICE, INBRED BALB C; TROPICAL CLIMATE;

EID: 79961110340     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-135     Document Type: Article

References (13)

1. Amphotericin B formulations and drug targeting. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S, J Pharm Sci 2008 97 2405 2425 10.1002/jps.21179 17893903
2. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Thornton SJ, Wasan KM, Expert Opin Drug Deliv 2009 6 271 284 10.1517/17425240902802861 19327044
3. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments. Lincopan N, Mamizuka EM, Carmona-Ribeiro AM, J Antimicrob Chemother 2003 52 412 418 10.1093/jac/dkg383 12917237 (Pubitemid 37120720)
4. Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio. Lincopan N, Borelli P, Fock R, Mamizuka EM, Carmona-Ribeiro AM, Exp Toxicol Pathol 2006 58 175 183 10.1016/j.etp.2006.07.002 16982179 (Pubitemid 44754742)
5. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Wasan EK, Bartlett K, Gershkovich P, Sivak O, Banno B, Wong Z, Gagnon J, Gates B, Leon CG, Wasan KM, Int J Pharm 2009 372 76 84 10.1016/j.ijpharm.2009.01.003 19236839
6. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, Werbovetz KA, Clement JG, Thornton SJ, J Infect Dis 2009 200 357 360 10.1086/600105 19545212
7. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). Gershkovich P, Sivak O, Wasan EK, Magil AB, Owen D, Clement JG, Wasan KM, J Antimicrob Chemother 2010 65 2610 2613 10.1093/jac/dkq358 20861140
8. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. Wasan EK, Gershkovich P, Zhao J, Zhu X, Werbovetz K, Tidwell RR, Clement JG, Thornton SJ, Wasan KM, PLoS Negl Trop Dis 2010 4 913 10.1371/journal.pntd.0000913 21151883
9. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. Gershkovich P, Wasan EK, Lin M, Sivak O, Leon CG, Clement JG, Wasan KM, J Antimicrob Chemother 2009 64 101 108 10.1093/jac/dkp140 19398459
10. Utility of endogenous creatinine clearance as a measure of renal function in mice. Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K, Kidney Int 2004 65 1959 1967 10.1111/j.1523-1755.2004.00600.x 15086941 (Pubitemid 38591050)
11. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (fungizone(R)): pooled analysis of published data. Kagan L, Gershkovich P, Wasan KM, Mager DE, AAPS J 2011 13 255 264 10.1208/s12248-011-9267-8 21431453
12. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M, Antimicrob Agents Chemother 1998 42 352 357 9527785 (Pubitemid 28114444)
13. Effect of Brazilian copaiba oils on Leishmania amazonensis. Santos AO, Ueda-Nakamura T, Dias Filho BP, Veiga Junior VF, Pinto AC, Nakamura CV, J Ethnopharmacol 2008 120 204 208 10.1016/j.jep.2008.08.007 18775772